Microtubule Inhibitors
- Name
- Microtubule Inhibitors
- Accession Number
- DBCAT002734
- Description
Not Available
- Drugs
Drug Drug Description Cabazitaxel An antineoplastic agent used in combination with corticosteroids to treat metastatic castration-resistant prostate cancer in patients previously treated with a docetaxel-containing treatment regimen. Docetaxel A taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer. Enfortumab vedotin An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. Eribulin A microtubule inhibitor used to treat metastatic breast cancer and metastatic or unresectable liposarcoma. Ixabepilone A microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines. Paclitaxel A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer. Paclitaxel ceribate Not Available Telisotuzumab vedotin An chemotherapeutic antibody-drug conjugate comprising a c-Met-directed antibody with a microtubule-disrupting small molecule payload. Tirbanibulin A tyrosine kinase and tubulin inhibitor used to treat actinic keratosis on the face or scalp. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. - Drugs & Drug Targets